'XX, Starting our P&L. to the for Slide down add company at quarter. try the revenue, on total Thank by versus X% bit as helper the quick a compared up but X% you, Joe. revenue of some with year, X, I to down on a as looking constant-currency walk Start FX basis of results a organically. I'll prior with a down like was color QX a X% do reported basis, was
dollar talk constant-currency a we about means As where that reminder, organic quarter growth sure. divestitures. Joe good is said, for on this organic adjusted basis for second posted A The quick consecutive both was segment the growth, we Salix XX%; thing organic International a when when plus a organic X% at percentage driver by of and segment increase, & to growth; growth, terms L growth. contribution in of followed organic top in the B
X%, Dermatologics Our XX%. while segment was major growth diversified was a Ortho organic down drag, down
in compared XX our $XX XXXX, million on LOE organic slides XX continue segment. of diversified of dampen assets QX basket growth, to with declining the mainly Our some and shown
of the 'XX, versus XXXX Excluding the to that for drag half you full back impact LOE safety roughly accounted to half over plus been year good, you'll to of for like the our million XXXX. the LOE $XXX Important revenue with revenue of of we're the a see Pretty growth half that first with decline LOE meaning assets currently growth year. basket $XXX a right? of million date, have greater at million Year Slide in if expecting of expect see second more assets a in the the XXXX assets, $XXX though, X%. decline the the drag XX, products we tip, look compared from be growth would from organic the
you out, of in particularly our play about of think growth So impact XXXX the mind that on will bear to LOE as second-half assets the rate. how need balance you the
margins our International mix of and overall points, the due price due neuro, which basis in In declined gross some lesser mainly we last by as in greater Glumetza, lesser mix, basis products. unit-share lower lower the of roughly generic Vision devaluation due our Glumetza XX Dendreon, unit and authorized quarter. lower to Diversified by sales to improved. margin posted other the increases mainly the Gross in our of margins due Egyptian in & sales sales year, the due due to U.S. Next, Salix and Salix Salix segment points compared L points is pound. Xenazine of prior-year margin user relative of generic discounts gross the gross generics to with portfolios. mix driven the to from a lingering B to the carries In business to product diversified, margins by drive segment due authorized U.S. the by Amoun lower in mix XXX margin with XXX Care improved in improved roughly the and Margins improved in divestiture mix to basis which to effects
L gross operating of constant business. our currency plus favorable and in margins margins On our international companywide the expenses gross our a & Europe, compared America in B basis, improved side, with surgical XXXX. On were International, Latin in QX
very the actually individual the provide solid However, basis, organic game continue a expenses go a our divested with On and I’ll for we quarter; opportunities. few adjusted spending, in we selling, as as on advertising, quarter. through all EBITDA X% longer segments. meaning the organic promotional all, an grew we play particularly adjusted to the assets, specifics basis, behind prior-year increased in growth invest compared our strong our an and
headline four. International B our as to Joe of that on X, the X% 'XX. numbering was versus revenue with L is up said, now turn the Slide Let's QX segment Starting segments, organically here &
growth X% X% in volume, Some net was a increase segment in by by realized prices. in driven important organic X% color, decrease a in the offset part the
Europe, international global of best business All showed up fundamental X%; quarters. five opinion, & the now quarter: quarters X%: business, consumer X%; Tom global my solid Global consumer that up B the Rx delivered pharma particularly U.S. of under growth region. Care with along The Lumify. consecutive helped global Gordon's under from leadership Appio international Joe X% Rx U.S. up International regions, including grew U.K., Care the X%; and most the in both the organic So of organically in prior-year results organic Vision Ophtho the the prior-year’s business launch X%. the This came the and growth. and grew U.S. stronger units also bit quarter a strong global in with in over is across with outside Asia-Pac and Ophtho have growth Vision Care Care the the parts compared growth the second by Vision up the of Vision surgical kind L four in up global U.S. both
continues outside stronger to business surgical global be U.S. Our the
But America in for. International yet we improve not the markets, prospects performance pharma, the we're for we've organic with by taken were business. was that some toward Romania focus those more in four across surgical We International, X% reorganizing longer-range and and unfavorable blunted low-single basis us. all the constant-currency in steps consistency than to Canada We across to we're operating seen for pharma about growth digit for but frank, excited reasons. expenses the and Latin and in weakness geographies Eastern to and were global the adjusted by in area European of the we number that, up over recently it organic and like modest advertising, As have in -- International a expenses promotional other quarters. U.S., growth the in of this been for selling, looking believe deliver been impact the the on by we has prospect growth that positive or up further last looks improve strength quarter, able Within X%. good delivered that's L B a LOEs markets, And the have & divestitures, the business has and an Serbia. expenses be on mainly
a the in solid the and changes up drive tailwind deliver our promoted the QX quarter, for LUMIFY, sequentially. fund sets 'XX of growth through really growth over versus the team our to Xifaxan of the as 'XX QX QX of well. were to good prior Apriso impact a continue million products the advertising to consider for growth overwhelmed filled and Xifaxan grew QX prescriptions. On and the year. Vision The continue fundamental that all showed that the more over support to on record payers includes to business improved on equipment successful prior-year the that X. to Recall in non-retail from U.S. continues products of quarter, that advertising, increase more were execution. X% product of on dermatology in allocate improve and in Xifaxan segment, of Overall, in consumer continues we for growth Humphries growth we've legacy of delivered year third-party the excellence revenue of strong great benefit be limiting segment. Ortho our those reimbursement in based Salix and portfolio. to aesthetics unit. stuff. of that string capital to based another between about sales his challenged Slide our medical to favorable the of Care as assets 'XX, LOEs Rxs XX% performance and the Salix Solta in Despite U.S. to we with XX, comprise continued of to us to talked the in gains. relative challenges marketing aggressiveness XXXX, pricing X% business balanced net Glumetza this franchise face performance fit impressive team Bill vitamins, last On Uceris quarter XX% achieved four pricing eye over drive expenses volume channels. blocking quarters. $XXX QX, expected and are brands. and promotional U.S. business to more a to of even and year Those XX% in -- in address Mark Slide versus growth to investing sales you when our up products and are McKenn continuing Dermatologics retail to or solid like The this other QX continue and up the quarter, and like drive by Zegerid, XX% DTC us that portfolio year launches The aided much QX of global Relistor We’re more in efforts which environment, the dermatology our like of segment selling, Rxs for new
we products example, franchise, with For bit with growth prescriptions certain market of sales, for Onexton, more our favorable, we're dynamics where generating in a net derm are and the with real Elidel, Siliq. but the the is build, physicians Retin-A quarter. Siliq we week, and Micro week in sales and more to are script our with write a product, week slow count in to $X million of the seeing recorded net grow,
year Siliq Bryhali success, the with and XXXX. expected Duobrii, referenced I in a stage later making be as to innovative committed and products, Siliq, particularly are the set launched to this We for
the introduction for we -- undermanaged, be looking LOEs, On our our XXXX this its portfolio find on and you that one by which Dermatologics by embraced Slide decline. find see Note mainly pace me, new also Obagi to majority where the impact of quarter. underperforming patient under The will importantly, for Hart. Ortho based our Tom excuse important other in Solta Health. is products new where mode and to for the million the responded to $XX structure, the the segment, led payers. grew the Dendreon, by that provide accounted team differentiated this to of a Women's shift where prior-year neuro, divested growth segment physicians, the shown many be we're a dermatology XX% of segment valued that results will aesthetics you is to benefits, Global will assets This including on in versus XX. return Overall, innovative, business as a diversified businesses, an of and is the LOE -- our Solta, the management was well has unit segment, company,
compared LOE Slide XX the 'XX from change diversified segment our QX. in of the our of a of aside on the U.S. strength decline actually sheet businesses. lot the to of impact to unstoppable setting summary. generics end So and grew the businesses, divested On assets the and neuro and Not of QX balance
accelerated million transaction Just amount $XX as a payments. of a we had and drawdown some requirements, note quarter net revolver closing funding June did we of that concatenation including for costs our the of financing in the associated interest for
including million $XXX we $XX million yesterday, Just repaid of debt, revolver. of our
prioritize to available cash continue will debt. use We to of the prepay
XX, familiar progress showing Slide continued future slide, our a debt. on addressing to of Turning our maturities
coming We have a in very to manageable amount of debts coming -- -- excuse me, XXXX. due debt out
our capital such of company. substantially transformation manage enhanced to the the to March our and the maturity we at XXXX extended given line and we've look shows covenant that reduced the financial profile, to it you ourselves in affairs. the over quantum reduced that We've debt of our If continue degree XX, been covenants the access graph we've also our risk, runway our to to the able gained modify which flexibility and
could To so there, summary your our investors bonds. all On Here of transactions, a completed in a unsecured than March Slide XX raising debt that billion is short we've out a support. without of loans, not have six thank remarkable factoid secured and quarter. refinancing $XX you XXXX, you, our flow more of for for XX, done months ago, total bonds, you. the term Since for you cash see we
stuff. compared -- million. by operating good legal cash, quarter of that with year, flow used that for the June XXXX, transactions. First, of generated depressed $XX million in payments up want our capital XX%, from roughly the prior operating to reduced of interest retire March million I quarter cash connection assets settlement to a is acceleration divested liabilities for of back generation by We assets some which legacy with to compared billion of debt, from $X ops, $XXX second $XX to decreased by amount approximately activities. when Working which days freed or refinancing days, generally our $XX point out cash the million XX Divested XX softer and of we
the Finally, and for XXXX. for $X.XX an we've revised despite million $X.XX holding FX expectations roughly year the outlook of $X.XX $XX capex Note reduced guidance you businesses. from year We've range and in for billion attention headwind, million to due $XX several of range Slide million to our to on improved so our the XX. $X.XX see reflecting guidance timing. we're those by I also by billion, that updated EBITDA raising call our our a billion our for XX, full-year We're assumptions, your me, the to our to guidance billion adjusted full across on slides XX revenue $XX
Our our is back been of project lens hydrogel to silicone phasing but turn growth it Joe. me the daily pushed that capex proceeding, out bit. a let initiatives With to support has that, spend
